Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334148 · ClinicalTrials.gov registry record · Phase 3
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
A Phase 3 study, sponsored by Adrian Hernandez.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,360
- Enrollment target
NCT04334148 is a Phase 3 study that has completed, run by Adrian Hernandez. The registered enrollment target is 1,360 participants.
The verdict
NCT04334148, a Phase 3 study, has completed, sponsored by Adrian Hernandez.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,360 participants
- Enrollment target
Study Summary
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.
Interventions
- DRUG Placebo oral tablet
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,360 participants |
| Start Date | 2020-04-22 |
| Est. Completion | 2021-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04334148
The ClinicalTrials.gov registry entry for NCT04334148 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adrian Hernandez, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04334148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04334148 about?
NCT04334148 is a clinical study titled "Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine". This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19. Eligible participants will be randomly assigned (1:1) to either treatment group (HCQ) or placebo in a double-blind fashion. Course of treatment is 30 days.
What is the current status of trial NCT04334148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,360 participants. The study started on 2020-04-22. Estimated completion is 2021-01-09.
What interventions are being tested in trial NCT04334148?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04334148?
This trial is sponsored by Adrian Hernandez, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.